HUE026062T2 - Apolipoprotein a-i mimics - Google Patents

Apolipoprotein a-i mimics Download PDF

Info

Publication number
HUE026062T2
HUE026062T2 HUE10741801A HUE10741801A HUE026062T2 HU E026062 T2 HUE026062 T2 HU E026062T2 HU E10741801 A HUE10741801 A HU E10741801A HU E10741801 A HUE10741801 A HU E10741801A HU E026062 T2 HUE026062 T2 HU E026062T2
Authority
HU
Hungary
Prior art keywords
leu
peptide
amino acid
glu
lys
Prior art date
Application number
HUE10741801A
Other languages
English (en)
Hungarian (hu)
Inventor
Jean-Louis Dasseux
Anna Shenderova Schwendeman
Lingyu Zhu
Original Assignee
Cerenis Therapeutics Holding Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerenis Therapeutics Holding Sa filed Critical Cerenis Therapeutics Holding Sa
Publication of HUE026062T2 publication Critical patent/HUE026062T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
HUE10741801A 2009-02-16 2010-02-12 Apolipoprotein a-i mimics HUE026062T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15296609P 2009-02-16 2009-02-16
US15296209P 2009-02-16 2009-02-16
US15296009P 2009-02-16 2009-02-16

Publications (1)

Publication Number Publication Date
HUE026062T2 true HUE026062T2 (en) 2016-05-30

Family

ID=42562076

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE10741801A HUE026062T2 (en) 2009-02-16 2010-02-12 Apolipoprotein a-i mimics
HUE15157397A HUE033661T2 (en) 2009-02-16 2010-02-12 Apolipoprotein A-I Mimics

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE15157397A HUE033661T2 (en) 2009-02-16 2010-02-12 Apolipoprotein A-I Mimics

Country Status (26)

Country Link
US (4) US8378068B2 (cg-RX-API-DMAC7.html)
EP (2) EP2396017B1 (cg-RX-API-DMAC7.html)
JP (2) JP5719783B2 (cg-RX-API-DMAC7.html)
KR (1) KR101688547B1 (cg-RX-API-DMAC7.html)
CN (2) CN104530223A (cg-RX-API-DMAC7.html)
AU (1) AU2010213568B2 (cg-RX-API-DMAC7.html)
CA (2) CA2752182C (cg-RX-API-DMAC7.html)
CY (1) CY1118809T1 (cg-RX-API-DMAC7.html)
DK (2) DK2396017T3 (cg-RX-API-DMAC7.html)
ES (2) ES2620478T3 (cg-RX-API-DMAC7.html)
HK (1) HK1209436A1 (cg-RX-API-DMAC7.html)
HR (2) HRP20150998T1 (cg-RX-API-DMAC7.html)
HU (2) HUE026062T2 (cg-RX-API-DMAC7.html)
IL (2) IL214576B (cg-RX-API-DMAC7.html)
LT (1) LT2939683T (cg-RX-API-DMAC7.html)
MX (3) MX2011008599A (cg-RX-API-DMAC7.html)
NZ (1) NZ594516A (cg-RX-API-DMAC7.html)
PH (1) PH12016501912A1 (cg-RX-API-DMAC7.html)
PL (2) PL2396017T3 (cg-RX-API-DMAC7.html)
PT (2) PT2396017E (cg-RX-API-DMAC7.html)
RU (2) RU2532222C2 (cg-RX-API-DMAC7.html)
SG (1) SG173624A1 (cg-RX-API-DMAC7.html)
SI (2) SI2939683T1 (cg-RX-API-DMAC7.html)
SM (2) SMT201700203T1 (cg-RX-API-DMAC7.html)
WO (1) WO2010093918A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201105997B (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2402823T3 (es) * 2006-06-01 2013-05-09 Institut De Cardiologie De Montreal Compuesto para uso en el tratamiento de estenosis valvular
US20120141576A1 (en) * 2007-03-15 2012-06-07 Benjamin Johnson Treatment of Dermatologic Skin Disorders
US20110059549A1 (en) 2007-05-09 2011-03-10 Coleman Matthew A Methods and systems for producing nanolipoprotein particles
US8907061B2 (en) 2008-01-11 2014-12-09 Lawrence Livermore National Security, Llc. Nanolipoprotein particles and related methods and systems for protein capture, solubilization, and/or purification
US10151037B2 (en) 2009-01-12 2018-12-11 Lawrence Livermore National Security, Llc Electrochemical flow-cell for hydrogen production and nicotinamide dependent target reduction, and related methods and systems
MX2011008599A (es) 2009-02-16 2011-11-18 Cerenis Therapeutics Sa Peptidos mimeticos de la apolipoproteina a-i.
US9052326B2 (en) 2011-01-26 2015-06-09 Institut National De La Santé Et De La Recherche Médicale (Inserm) Method for assessing a subject's risk of having a cardiovascular disease
LT2673296T (lt) * 2011-02-07 2019-02-25 Cerenis Therapeutics Holding Sa Lipoproteino kompleksai ir jų gamyba ir jų panaudojimai
US9644038B2 (en) 2011-12-21 2017-05-09 The Regents Of The University Of California Apolipoprotein nanodiscs with telodendrimer
US9702807B2 (en) 2012-06-16 2017-07-11 Ningbo Alabama, Llc Measurement of serum lipoproteins
US9239280B2 (en) 2012-06-16 2016-01-19 Atherotech, Inc. Measurement of serum lipoproteins
RU2016144908A (ru) 2014-05-02 2018-06-05 Серени Терапеутикс Холдинг Са Маркеры hdl-терапии
AU2016238290B9 (en) 2015-03-25 2019-06-13 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
US12226529B2 (en) 2015-08-25 2025-02-18 Lawrence Livermore National Security, Llc Stable nanolipoprotein particles and related compositions methods and systems
US11279749B2 (en) 2015-09-11 2022-03-22 Lawrence Livermore National Security, Llc Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation
US20190201540A1 (en) * 2016-05-24 2019-07-04 Stc Unm Immunogens, compositions, and methods for treating dyslipidemia
US12083223B2 (en) 2017-05-02 2024-09-10 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions methods and systems for loading RNA
US11207422B2 (en) 2017-05-02 2021-12-28 Lawrence Livermore National Security, Llc MOMP telonanoparticles, and related compositions, methods and systems
TW201919712A (zh) * 2017-08-10 2019-06-01 法商塞勒尼斯醫療控股公司 運送子(cargomers)
US20190046608A1 (en) * 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Sa Apomers
KR20260012291A (ko) 2018-07-12 2026-01-26 더 리젠츠 오브 더 유니버시티 오브 미시간 면역 반응을 조절할 수 있는 금속 함유 제형의 조성물 및 방법
WO2021113514A1 (en) * 2019-12-05 2021-06-10 Fresenius Kabi Usa, Llc Method for analyzing degarelix and associated products
KR20230004605A (ko) 2020-04-16 2023-01-06 아비오닉스 파마 에스에이 지질 결합 단백질-기반 복합체를 사용하여 급성 상태를 치료하는 방법
WO2021209808A1 (en) * 2020-04-16 2021-10-21 Abionyx Pharma Sa Cer-001 therapy for treating kidney disease
AU2021254856A1 (en) * 2020-04-16 2022-11-10 Abionyx Pharma Sa CER-001 therapy for treating kidney disease
CA3197168A1 (en) 2020-10-01 2022-04-07 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
US20240050522A1 (en) * 2020-12-11 2024-02-15 The Regents Of The University Of Michigan COMPOSITIONS AND METHODS FOR PREVENTING, ATTENUATING, AND TREATING MEDICAL CONDITIONS WITH sHDL NANOPARTICLES
CA3216226A1 (en) 2021-04-15 2022-10-20 Abionyx Pharma Sa Use of lipid binding protein-based complexes in organ preservation solutions
CN114940711B (zh) * 2021-10-25 2023-05-12 中山大学 载脂蛋白a-i模拟肽及其应用
CN119317440A (zh) 2022-04-06 2025-01-14 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗白细胞增多、内皮功能障碍和心脏炎的方法
US20250230208A1 (en) 2022-04-06 2025-07-17 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
CA3258787A1 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa METHODS OF TREATMENT OF HYPERINFLAMMATORY DISEASES USING LIPID-BINDING PROTEIN COMPLEXES
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
US12060148B2 (en) 2022-08-16 2024-08-13 Honeywell International Inc. Ground resonance detection and warning system and method
KR20260010675A (ko) 2023-01-13 2026-01-21 아비오닉스 파마 에스에이 지질 결합 단백질 분자 치료
IL327995A (en) 2023-10-31 2026-06-01 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (cg-RX-API-DMAC7.html) 1977-08-05 1981-02-13 Battelle Memorial Institute
CA1173360A (en) 1979-06-22 1984-08-28 Jurg Schrank Pharmaceutical preparations
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4643988A (en) 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
JPS61152632A (ja) 1984-12-26 1986-07-11 Dai Ichi Seiyaku Co Ltd 抗動脈硬化剤
US4857319A (en) 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5972890A (en) 1988-05-02 1999-10-26 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5220043A (en) 1991-03-21 1993-06-15 Ohio University Synthesis of D-erythro-sphingomyelins
JPH0559081A (ja) 1991-08-29 1993-03-09 Kirin Brewery Co Ltd 新規スフインゴ糖脂質、その製造法および使用
EP0644897B1 (en) 1992-06-12 1998-09-16 N.V. Innogenetics S.A. New peptides and proteins, process for their preparation and their use as cholesterol acceptors
TW261533B (cg-RX-API-DMAC7.html) 1992-07-16 1995-11-01 Kirin Brewery
US5674855A (en) 1992-08-12 1997-10-07 The Rogosin Institute Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
HUT72495A (en) 1992-10-01 1996-05-28 Cold Spring Harbor Lab Complex combinatorial chemical libraries encoded with tags
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
FR2734568B1 (fr) 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
EP1053243B1 (en) 1998-02-12 2011-03-30 Emory University Sphingolipid derivatives and their methods of use
US6459003B1 (en) 1999-04-01 2002-10-01 Esperion Therapeutics, Inc. Ether compounds
DK1290013T3 (da) * 2000-04-21 2006-06-26 Amgen Inc Apo-A1/All-peptidderivater
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
NZ532217A (en) 2001-09-28 2006-12-22 Esperion Therapeutics Inc Use of an alpha helical apolipoprotein or HDL associating protein adapted to be administered locally to prevent or reduce stenosis or restenosis or to stabilize a plaque
MXPA04011312A (es) 2002-05-17 2005-02-14 Esperion Therapeutics Inc Metodo para el tratamiento de desordenes dislipidemicos.
DE10237571A1 (de) 2002-08-13 2004-02-26 Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin Endovaskuläres Implantat mit aktiver Beschichtung
JP2007536200A (ja) * 2003-07-17 2007-12-13 ミジェニックス インコーポレイテッド リポペプチド抗生物質誘導体の組成物およびその使用方法
JP5048486B2 (ja) 2004-07-16 2012-10-17 トラスティーズ オブ タフツ カレッジ アポリポタンパク質a1の模倣物とその使用
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
AU2006264567A1 (en) * 2005-05-05 2007-01-11 Valorisation Hsj, Societe En Commandite Cytokine receptor modulators and uses thereof
TW200744627A (en) 2006-02-21 2007-12-16 Pfizer Prod Inc Methods for the treatment of macular degeneration and related eye conditions
ES2402823T3 (es) 2006-06-01 2013-05-09 Institut De Cardiologie De Montreal Compuesto para uso en el tratamiento de estenosis valvular
US20080138284A1 (en) 2006-09-26 2008-06-12 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
WO2008094905A2 (en) 2007-01-29 2008-08-07 Lipid Sciences, Inc. Encapsulated hdl mimetic peptides
US7956035B2 (en) 2007-03-01 2011-06-07 Csl Limited Treatment of endothelial dysfunction in diabetic patients
AU2008266753A1 (en) 2007-06-20 2008-12-24 Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.P.A. ApoA-1 peptide mimetics
US9173890B2 (en) * 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
EP2389189A4 (en) 2009-01-23 2012-12-19 Inst Cardiologie Montreal METHOD FOR PREVENTING AND TREATING DIASTOLIC DYSFUNCTION WITH A MIMETAL APOLIPOPROTEIN A1 (APOA1) -PEPTIDE / PHOSPHOLIPID COMPLEX
MX2011008599A (es) 2009-02-16 2011-11-18 Cerenis Therapeutics Sa Peptidos mimeticos de la apolipoproteina a-i.
WO2012012870A1 (en) * 2010-07-28 2012-02-02 Institut De Cardiologie De Montreal Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex
SG11201506456VA (en) 2013-03-15 2015-09-29 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins

Also Published As

Publication number Publication date
US9981008B2 (en) 2018-05-29
SMT201700203T1 (it) 2017-05-08
AU2010213568A1 (en) 2011-09-01
RU2014134333A (ru) 2016-03-20
IL240357A (en) 2017-11-30
EP2396017B1 (en) 2015-07-01
CN104530223A (zh) 2015-04-22
SI2396017T1 (sl) 2015-12-31
RU2532222C2 (ru) 2014-10-27
IL214576B (en) 2019-05-30
HUE033661T2 (en) 2017-12-28
HRP20150998T1 (hr) 2015-11-20
HRP20170294T1 (hr) 2017-04-21
CN102395375B (zh) 2015-01-14
PL2396017T3 (pl) 2015-12-31
IL214576A0 (en) 2011-09-27
KR20120004412A (ko) 2012-01-12
US20150141330A1 (en) 2015-05-21
WO2010093918A1 (en) 2010-08-19
CY1118809T1 (el) 2018-01-10
JP2015110677A (ja) 2015-06-18
RU2011138011A (ru) 2013-03-27
ES2620478T3 (es) 2017-06-28
JP2012518006A (ja) 2012-08-09
EP2939683B1 (en) 2017-01-04
KR101688547B1 (ko) 2016-12-21
CA2982157A1 (en) 2010-08-19
CN102395375A (zh) 2012-03-28
DK2939683T3 (en) 2017-03-13
MX2011008599A (es) 2011-11-18
DK2396017T3 (en) 2015-09-14
US20100267631A1 (en) 2010-10-21
EP2939683A1 (en) 2015-11-04
MX386110B (es) 2025-03-18
PL2939683T3 (pl) 2017-07-31
CA2752182A1 (en) 2010-08-19
SMT201500318B (it) 2016-02-25
EP2396017A4 (en) 2013-03-27
PH12016501912A1 (en) 2019-11-18
ZA201105997B (en) 2013-10-30
JP5719783B2 (ja) 2015-05-20
US20160324923A1 (en) 2016-11-10
IL240357A0 (en) 2015-09-24
AU2010213568B2 (en) 2014-11-20
US9388232B2 (en) 2016-07-12
HK1165987A1 (en) 2012-10-19
US20130231459A1 (en) 2013-09-05
PT2939683T (pt) 2017-04-07
US8378068B2 (en) 2013-02-19
CA2752182C (en) 2017-11-28
EP2396017A1 (en) 2011-12-21
HK1209436A1 (en) 2016-04-01
MX343654B (es) 2016-11-16
US8993597B2 (en) 2015-03-31
PT2396017E (pt) 2015-10-22
SI2939683T1 (sl) 2017-04-26
NZ594516A (en) 2012-12-21
LT2939683T (lt) 2017-03-27
SG173624A1 (en) 2011-09-29
ES2554853T3 (es) 2015-12-23

Similar Documents

Publication Publication Date Title
US9981008B2 (en) Apolipoprotein A-I mimics
AU2005201985B2 (en) Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
AU746686B2 (en) Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
KR100650974B1 (ko) 비정상 지혈증 장애 치료용 아포리포단백질 a-i 유사 펩티드
AU2018203258A1 (en) Lipoprotein complexes and manufacturing and uses thereof
AU2014268255B2 (en) Apolipoprotein a-i mimics
HK1165987B (en) Apolipoprotein a-i mimics